213 related articles for article (PubMed ID: 28735629)
1. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer.
Kogan L; Laskov I; Amajoud Z; Abitbol J; Yasmeen A; Octeau D; Fatnassi A; Kessous R; Eisenberg N; Lau S; Gotlieb WH; Salvador S
Gynecol Oncol; 2017 Oct; 147(1):30-35. PubMed ID: 28735629
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
3. Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Vandenput I; Vergote I; Leunen K; Berteloot P; Neven P; Amant F
Int J Gynecol Cancer; 2009 Aug; 19(6):1147-51. PubMed ID: 19820384
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Katsumata N; Yasuda M; Takahashi F; Isonishi S; Jobo T; Aoki D; Tsuda H; Sugiyama T; Kodama S; Kimura E; Ochiai K; Noda K;
Lancet; 2009 Oct; 374(9698):1331-8. PubMed ID: 19767092
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Sivakumaran T; Mileshkin L; Grant P; Na L; DeFazio A; Friedlander M; Obermair A; Webb PM; Au-Yeung G;
Gynecol Oncol; 2020 Jul; 158(1):47-53. PubMed ID: 32381362
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin plus paclitaxel weekly dose-dense chemotherapy for high-grade ovarian cancer: A re-evaluation.
Kessous R; Matanes E; Laskov I; Wainstock T; Abitbol J; Yasmeen A; Salvador S; Lau S; Gotlieb WH
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):453-458. PubMed ID: 33048344
[TBL] [Abstract][Full Text] [Related]
9. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
10. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
Secord AA; Havrilesky LJ; Carney ME; Soper JT; Clarke-Pearson DL; Rodriguez GC; Berchuck A
Int J Clin Oncol; 2007 Feb; 12(1):31-6. PubMed ID: 17380438
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study.
Vrdoljak J; Boban T; Petrić Miše B; Boraska Jelavić T; Bajić Ž; Tomić S; Vrdoljak E
Jpn J Clin Oncol; 2019 Apr; 49(4):347-353. PubMed ID: 30796833
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
14. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
Simpkins F; Drake R; Escobar PF; Nutter B; Rasool N; Rose PG
Gynecol Oncol; 2015 Feb; 136(2):240-5. PubMed ID: 25485782
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
[TBL] [Abstract][Full Text] [Related]
17. Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma--a retrospective study.
Safra T; Shamai S; Greenberg J; Veizman A; Shpigel S; Matcejevsky D; Pelles S; Inbar M; Levy T; Grisaru D
Gynecol Oncol; 2014 Jan; 132(1):18-22. PubMed ID: 23850468
[TBL] [Abstract][Full Text] [Related]
18. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
Lupe K; Kwon J; D'Souza D; Gawlik C; Stitt L; Whiston F; Nascu P; Wong E; Carey MS
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):110-6. PubMed ID: 17084542
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience.
Lan C; Huang X; Cao X; Huang H; Feng Y; Huang Y; Liu J
Expert Opin Pharmacother; 2013 Apr; 14(5):535-42. PubMed ID: 23480059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]